Cellebrite DI Ltd.
CLBT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $401 | $325 | $271 | $246 |
| % Growth | 23.4% | 20.1% | 9.9% | – |
| Cost of Goods Sold | $63 | $53 | $51 | $43 |
| Gross Profit | $339 | $272 | $220 | $204 |
| % Margin | 84.4% | 83.6% | 81.3% | 82.7% |
| R&D Expenses | $98 | $84 | $81 | $66 |
| G&A Expenses | $51 | $43 | $41 | $48 |
| SG&A Expenses | $183 | $154 | $138 | $124 |
| Sales & Mktg Exp. | $132 | $111 | $97 | $76 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $282 | $239 | $219 | $190 |
| Operating Income | $57 | $33 | $1 | $14 |
| % Margin | 14.2% | 10.2% | 0.4% | 5.6% |
| Other Income/Exp. Net | -$333 | -$109 | $120 | $68 |
| Pre-Tax Income | -$276 | -$76 | $121 | $82 |
| Tax Expense | $7 | $6 | -$0 | $11 |
| Net Income | -$283 | -$81 | $121 | $71 |
| % Margin | -70.5% | -24.9% | 44.6% | 29% |
| EPS | -1.35 | -0.43 | 0.64 | 0.5 |
| % Growth | -214% | -167.2% | 28% | – |
| EPS Diluted | -1.35 | -0.43 | 0.59 | 0.44 |
| Weighted Avg Shares Out | 209 | 190 | 183 | 144 |
| Weighted Avg Shares Out Dil | 209 | 190 | 195 | 162 |
| Supplemental Information | – | – | – | – |
| Interest Income | $18 | $9 | $2 | $1 |
| Interest Expense | $350 | $0 | $0 | $0 |
| Depreciation & Amortization | $11 | $10 | $9 | $7 |
| EBITDA | $68 | -$65 | $130 | $89 |
| % Margin | 16.8% | -19.9% | 48.1% | 36.3% |